building BDUCA
institution Biblioteca Digital (UCA)
id BDUCA--investigacion:therapeutic-application-melatonin-mild
author Cardinali, Daniel P.
Vigo, Daniel E.
Olivar, Natividad
Vidal, María Florencia
Furio, Analía M.
Brusco, Luis I.
spellingShingle Cardinali, Daniel P.
Vigo, Daniel E.
Olivar, Natividad
Vidal, María Florencia
Furio, Analía M.
Brusco, Luis I.
ENFERMEDAD DE ALZHEIMER
MELATONINA
BENZODIAZEPINAS
TEST NEUROPSICOLOGICOS
DETERIORO COGNITIVO LEVE
Therapeutic application of melatonin in mild cognitive impairment
Abstract: Mild cognitive impairment (MCI) is an etiologically heterogeneous syndrome defined by cognitive impairment in advance of dementia. We previously reported in a retrospective analysis that daily 3 - 9 mg of a fast-release melatonin preparation given p. o. at bedtime for up to 3 years significantly improved cognitive and emotional performance and daily sleep/wake cycle in MCI patients. In a follow up of that study we now report data from another series of 96 MCI outpatients, 61 of who had received daily 3 - 24 mg of a fast-release melatonin preparation p. o. at bedtime for 15 to 60 months. Melatonin was given in addition to the standard medication prescribed by the attending psychiatrist. Patients treated with melatonin exhibited significantly better performance in Mini–Mental State Examination and the cognitive subscale of the Alzheimer’s disease Assessment Scale. After application of a neuropsychological battery comprising a Mattis´ test, Digit-symbol test, Trail A and B tasks and the Rey´s verbal test, better performance was found in melatonin-treated patients for every parameter tested. Abnormally high Beck Depression Inventory scores decreased in melatonin-treated patients, concomitantly with the improvement in the quality of sleep and wakefulness. The comparison of the medication profile in both groups of MCI patients indicated that 9.8% in the melatonin group received benzodiazepines vs. 62.8% in the non-melatonin group. The results further support that melatonin can be a useful add-on drug for treating MCI in a clinic environment
topic ENFERMEDAD DE ALZHEIMER
MELATONINA
BENZODIAZEPINAS
TEST NEUROPSICOLOGICOS
DETERIORO COGNITIVO LEVE
topic_facet ENFERMEDAD DE ALZHEIMER
MELATONINA
BENZODIAZEPINAS
TEST NEUROPSICOLOGICOS
DETERIORO COGNITIVO LEVE
title Therapeutic application of melatonin in mild cognitive impairment
title_full Therapeutic application of melatonin in mild cognitive impairment
title_fullStr Therapeutic application of melatonin in mild cognitive impairment
title_full_unstemmed Therapeutic application of melatonin in mild cognitive impairment
title_short Therapeutic application of melatonin in mild cognitive impairment
contents Abstract: Mild cognitive impairment (MCI) is an etiologically heterogeneous syndrome defined by cognitive impairment in advance of dementia. We previously reported in a retrospective analysis that daily 3 - 9 mg of a fast-release melatonin preparation given p. o. at bedtime for up to 3 years significantly improved cognitive and emotional performance and daily sleep/wake cycle in MCI patients. In a follow up of that study we now report data from another series of 96 MCI outpatients, 61 of who had received daily 3 - 24 mg of a fast-release melatonin preparation p. o. at bedtime for 15 to 60 months. Melatonin was given in addition to the standard medication prescribed by the attending psychiatrist. Patients treated with melatonin exhibited significantly better performance in Mini–Mental State Examination and the cognitive subscale of the Alzheimer’s disease Assessment Scale. After application of a neuropsychological battery comprising a Mattis´ test, Digit-symbol test, Trail A and B tasks and the Rey´s verbal test, better performance was found in melatonin-treated patients for every parameter tested. Abnormally high Beck Depression Inventory scores decreased in melatonin-treated patients, concomitantly with the improvement in the quality of sleep and wakefulness. The comparison of the medication profile in both groups of MCI patients indicated that 9.8% in the melatonin group received benzodiazepines vs. 62.8% in the non-melatonin group. The results further support that melatonin can be a useful add-on drug for treating MCI in a clinic environment
url http://bibliotecadigital.uca.edu.ar/repositorio/investigacion/therapeutic-application-melatonin-mild.pdf
format Artículo
genre Artículo
genre_facet Artículo
era 2012
era_facet 2012
publishDate 2012
language English
_version_ 1630392006206291968
score 12,815243